Inmune Bio (INMB) Other Working Capital Changes (2021 - 2026)
Inmune Bio (INMB) posted Other Working Capital Changes of -$20000.0 for Q1 2026, down 119.23% sequentially from $104000.0 in Q4 2025, and down 150.0% YoY from $40000.0 in Q1 2025.
Inmune Bio (INMB) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Inmune Bio has reported Other Working Capital Changes for 5 years, with the latest figure at -$20000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 150.0% year-over-year to -$20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69000.0 (up 355.56% YoY) and the FY2025 annual result came in at $43000.0, up 272.0% from the prior year.
- Other Working Capital Changes retreated to -$20000.0 in Q1 2026 per INMB's latest filing, from $104000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $521000.0 in Q2 2025 and troughed at -$401000.0 in Q1 2024.
- A 5-year average of $7384.6 and a median of -$1000.0 in 2023 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2023 and 2025: Other Working Capital Changes plunged 200.0% in 2023, then surged 1585.71% in 2025.
- Over 5 years, Other Working Capital Changes stood at -$116000.0 in 2022, then soared by 108.62% to $10000.0 in 2023, then slumped by 170.0% to -$7000.0 in 2024, then soared by 1585.71% to $104000.0 in 2025, then slumped by 119.23% to -$20000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$20000.0, $104000.0, and -$8000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -146,000.00 |
| Jun 30, 2026 | -146,000.00 |
| Jun 30, 2026 | -146,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Dec 31, 2025 | -151,000.00 |
| Dec 31, 2025 | -151,000.00 |
| Dec 31, 2025 | -151,000.00 |
| Sep 30, 2025 | 176,000.00 |
| Sep 30, 2025 | 176,000.00 |
| Sep 30, 2025 | 176,000.00 |
| Jun 30, 2025 | 521,000.00 |
| Jun 30, 2025 | 521,000.00 |
| Jun 30, 2025 | 521,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |